CO6612264A2 - Proteinas terapeuticas de la union a dll 4 - Google Patents

Proteinas terapeuticas de la union a dll 4

Info

Publication number
CO6612264A2
CO6612264A2 CO12168478A CO12168478A CO6612264A2 CO 6612264 A2 CO6612264 A2 CO 6612264A2 CO 12168478 A CO12168478 A CO 12168478A CO 12168478 A CO12168478 A CO 12168478A CO 6612264 A2 CO6612264 A2 CO 6612264A2
Authority
CO
Colombia
Prior art keywords
dll4
dll
binding
therapeutic proteins
binding proteins
Prior art date
Application number
CO12168478A
Other languages
English (en)
Inventor
Yingchun Li
Jijie James Gu
Susan E Morgan-Lappe
Mingjiu Chen
Chung-Ming Hsieh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO6612264A2 publication Critical patent/CO6612264A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen las proteínas de unión a DLL4, incluyendo anticuerpos, anticuerpos de CDR injertada, anticuerpos humanizados, y fragmentos de unión a DLL4 de los mismos, proteínas que se unen a DLL4 con alta afinidad, y proteínas de unión a DLL4 que neutralizan la actividad de DLL4 y/o VEGF. Las proteínas de unión a DLL4 son útiles para el tratamiento o prevención de cánceres y tumores y especialmente para el tratamiento o prevención de angiogénesis de tumor.
CO12168478A 2010-03-02 2012-09-26 Proteinas terapeuticas de la union a dll 4 CO6612264A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30949410P 2010-03-02 2010-03-02

Publications (1)

Publication Number Publication Date
CO6612264A2 true CO6612264A2 (es) 2013-02-01

Family

ID=44531508

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12168478A CO6612264A2 (es) 2010-03-02 2012-09-26 Proteinas terapeuticas de la union a dll 4

Country Status (26)

Country Link
US (4) US9115195B2 (es)
EP (3) EP3680253A3 (es)
JP (2) JP5964249B2 (es)
KR (2) KR20180044441A (es)
CN (2) CN102906113B (es)
AR (1) AR080452A1 (es)
AU (1) AU2011223919B2 (es)
BR (1) BR112012021941A2 (es)
CA (1) CA2791631A1 (es)
CL (1) CL2012002416A1 (es)
CO (1) CO6612264A2 (es)
CR (1) CR20120454A (es)
DO (2) DOP2012000240A (es)
EC (1) ECSP12012194A (es)
GT (1) GT201200253A (es)
MX (1) MX348312B (es)
MY (1) MY160628A (es)
NZ (1) NZ602734A (es)
PE (1) PE20130580A1 (es)
RU (2) RU2016146198A (es)
SG (2) SG183872A1 (es)
TW (1) TWI511742B (es)
UA (1) UA112743C2 (es)
UY (2) UY33254A (es)
WO (1) WO2011109298A2 (es)
ZA (1) ZA201206552B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101477824B1 (ko) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
EP2282769A4 (en) * 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
WO2009149189A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
TR201818814T4 (tr) * 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
RU2016146198A (ru) 2010-03-02 2018-12-19 Эббви Инк. Терапевтические dll4-связывающие белки
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
RS58201B1 (sr) 2011-09-23 2019-03-29 Oncomed Pharm Inc Vegf/dll4 vezujući agensi i njihova upotreba
CN103917562B (zh) * 2011-09-30 2016-07-06 瑞泽恩制药公司 抗-ErbB3抗体及其用途
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
AR092325A1 (es) * 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP2914961A4 (en) 2012-10-31 2016-04-20 Oncomed Pharm Inc METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
TWI601745B (zh) 2012-11-01 2017-10-11 艾伯維有限公司 抗－ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
CN103254281B (zh) * 2013-05-30 2014-09-03 南通广泰生化制品有限公司 一种微管蛋白聚合剂多肽6及其应用
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
ES2744526T3 (es) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anticuerpos anti-MCAM y métodos de uso asociados
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
KR101943989B1 (ko) 2015-06-05 2019-01-30 삼성전자주식회사 데이터를 송수신하는 방법, 서버 및 단말기
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN105267953B (zh) * 2015-09-15 2018-08-31 浙江大学 Dll4细胞因子在制备治疗暴发性肝功能衰竭药剂中的应用
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
CN105384818B (zh) * 2015-12-17 2020-02-18 中国药科大学 抗人Delta like 4单克隆抗体及其应用
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017204475A1 (ko) * 2016-05-24 2017-11-30 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN107557343B (zh) * 2017-08-09 2020-09-25 苏州大学附属儿童医院 抗人dll4单克隆抗体3f9
CN107383195B (zh) * 2017-08-09 2020-04-21 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12的制备方法
US20220017610A1 (en) * 2018-11-16 2022-01-20 The Brigham And Women`S Hospital, Inc. Antibodies Blocking DLL4-Mediated Notch Signalling
CN113388030B (zh) * 2021-08-17 2021-11-23 上海浙江大学高等研究院 单克隆抗体32c7及其制备方法和用途

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985A (en) 1848-12-26 Pianoforte-action
US5934A (en) 1848-11-21 Improvement in harvesting-machines
US320A (en) 1837-07-31 John dainty
US272A (en) 1837-07-17 Floating bey-dock
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0204571B1 (en) 1985-06-07 1992-01-22 Ici Americas Inc. Selected difluoro derivatives
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU652539B2 (en) 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
WO1992003461A1 (en) 1990-08-24 1992-03-05 Ixsys, Inc. Methods of synthesizing oligonucleotides with random codons
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
JP3298879B2 (ja) 1990-12-20 2002-07-08 イグジス，インコーポレイテッド 結合タンパク質の最適化
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
CA2106299C (en) 1991-03-18 2001-02-06 Junming Le Monoclonal and chimeric antibodies specific for human tumor necrosis factor
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1994018219A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996033266A1 (en) 1995-04-21 1996-10-24 Cell Genesys, Inc. Generation of large genomic dna deletions
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996036358A1 (en) * 1995-05-15 1996-11-21 Cedars-Sinai Medical Center Compositions and methods for inhibiting xenograft rejection
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
PL188192B1 (pl) 1996-02-09 2004-12-31 Abbott Lab Bermuda Ltd Izolowane ludzkie przeciwciało albo jego część wiążąca antygen, rekombinowane ludzkie przeciwciało albo jego część wiążąca antygen, kompozycje farmaceutyczne, izolowane kwasy nukleinowe, rekombinowany wektor ekspresyjny, komórka gospodarza, sposób syntetyzowania przeciwciała ludzkiego, które wiąże ludzki TNFalfa, sposób hamowania aktywności ludzkiego TNFalfa in vitro, przeciwciało albo jego częśćwiążąca antygen, zastosowanie przeciwciała albo jego części wiążącej antygen
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
GB9623236D0 (en) 1996-11-07 1997-01-08 Imperial College Notch
CA2271248C (en) 1996-11-07 2009-08-11 Jonathan Robert Lamb Use of a notch ligand in immunotherapy
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU8691398A (en) 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6833492B2 (en) * 1998-08-28 2004-12-21 E. I. Du Pont De Nemours And Company Nitrogen transport metabolism
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EA006972B1 (ru) 1998-12-23 2006-06-30 Пфайзер Инк. Моноклональное антитело человека к ctla-4 и способы его применения
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
TR200501367T2 (tr) 1999-03-25 2005-09-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
WO2001077335A2 (fr) * 2000-04-11 2001-10-18 Institut Pasteur Genome de listeria monocytogenes, polypeptides et utilisations
AU4761601A (en) 2000-04-11 2001-10-23 Genentech Inc Multivalent antibodies and uses therefor
AU2001259432B2 (en) 2000-05-03 2005-04-21 Amgen Inc. Modified peptides, comprising an FC domain, as therapeutic agents
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
ATE309385T1 (de) 2000-06-28 2005-11-15 Glycofi Inc Verfahren für die herstellung modifizierter glykoproteine
US7491516B2 (en) 2000-06-29 2009-02-17 Abbott Laboratories Dual specificity antibodies and methods of making and using
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030176672A1 (en) * 2001-02-13 2003-09-18 Susana Salceda Compositions and methods relating to breast specific genes and proteins
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
JPWO2003046009A1 (ja) * 2001-11-27 2005-04-07 持田製薬株式会社 抗ＩＬ１３レセプターα１中和抗体
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7416868B2 (en) * 2003-01-21 2008-08-26 Thallion Pharmaceuticals, Inc. Polyene polyketides, processes for their production and their use as a pharmaceutical
BRPI0411127A (pt) * 2003-06-10 2006-05-23 Univ Melbourne composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
WO2005093060A1 (ja) * 2004-03-26 2005-10-06 Nippon Shokubai Co., Ltd. １，３−プロパンジオール及び／又は３−ヒドロキシプロピオン酸を製造する方法
AU2005321021B2 (en) * 2004-06-23 2011-11-24 Ian A. Ferguson Agents and methods for early diagnosis and monitoring of Alzheimer's disease and other neurological disorders
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
WO2006063150A2 (en) 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20100021953A1 (en) * 2005-08-03 2010-01-28 Astrazeneca Ab Method for Identifying an Agent that Modulates Arginine Transport in a Chondrocyte
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
CN101330925A (zh) * 2005-12-16 2008-12-24 瑞泽恩制药公司 用d114拮抗剂抑制肿瘤生长的治疗方法
AR061245A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Composiciones y metodos para la modulacion del desarrollo vascular
US7803377B2 (en) * 2006-06-06 2010-09-28 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CN101490084A (zh) * 2006-06-06 2009-07-22 健泰科生物技术公司 抗dll4抗体及其使用方法
RU2429876C2 (ru) * 2006-08-07 2011-09-27 Ридженерон Фармасьютикалз, Инк. ТЕРАПЕВТИЧЕСКИЕ СПОСОБЫ ЛЕЧЕНИЯ ВАСКУЛЯРНЫХ ЗАБОЛЕВАНИЙ ГЛАЗ АНТАГОНИСТАМИ Dll4
PE20080739A1 (es) * 2006-08-11 2008-06-14 Schering Corp Anticuerpos para il-17a
KR101477824B1 (ko) 2006-09-29 2015-01-02 온코메드 파마슈티칼스, 인크. 암의 진단 및 치료를 위한 조성물 및 방법
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN101210049A (zh) * 2006-12-30 2008-07-02 上海新生源医药研究有限公司 一种免疫抑制剂-抗cd25嵌合单克隆抗体
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
NZ603245A (en) * 2007-02-23 2014-04-30 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
BRPI0815848A2 (pt) * 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
NZ585556A (en) * 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
CN101925611A (zh) * 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
NZ600979A (en) 2008-01-15 2014-01-31 Abbott Lab Improved mammalian expression vectors and uses thereof
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
CA2720763A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
WO2009126082A1 (en) 2008-04-11 2009-10-15 Eric Carlson Threading device
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009149189A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5674654B2 (ja) 2008-07-08 2015-02-25 アッヴィ・インコーポレイテッド プロスタグランジンｅ２二重可変ドメイン免疫グロブリンおよびその使用
AU2009268584A1 (en) 2008-07-08 2010-01-14 Abbvie Inc. Prostaglandin E2 binding proteins and uses thereof
AU2009294415B2 (en) * 2008-09-19 2015-09-24 Medimmune Llc Antibodies directed to DLL4 and uses thereof
AU2009298501A1 (en) 2008-09-30 2010-04-08 Abbvie Inc. Improved antibody libraries
KR20110097913A (ko) 2008-12-04 2011-08-31 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
MX2011009362A (es) 2009-03-05 2011-09-26 Abbott Lab Proteinas de union a il-17.
JP2012525155A (ja) 2009-05-01 2012-10-22 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびこの使用
WO2010127294A2 (en) 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
RU2016146198A (ru) 2010-03-02 2018-12-19 Эббви Инк. Терапевтические dll4-связывающие белки
NZ628792A (en) 2010-05-14 2016-03-31 Abbvie Inc Il-1 binding proteins
TW201204831A (en) 2010-06-24 2012-02-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012018790A2 (en) 2010-08-03 2012-02-09 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
MX2013004979A (es) 2010-11-02 2013-07-30 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
WO2012061558A2 (en) 2010-11-04 2012-05-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
RU2015134562A (ru) 2011-02-08 2018-12-24 Эббви Инк. Лечение остеоартрита и боли
RS58201B1 (sr) 2011-09-23 2019-03-29 Oncomed Pharm Inc Vegf/dll4 vezujući agensi i njihova upotreba
TW201323441A (zh) 2011-10-24 2013-06-16 Abbvie Inc 抗ｔｎｆ之雙特異性免疫結合物
US9803009B2 (en) 2011-10-24 2017-10-31 Abbvie Inc. Immunobinders directed against TNF
BR112014012121A2 (pt) 2011-11-21 2019-09-24 Abbvie Inc proteínas ligantes
US20130195871A1 (en) 2011-12-30 2013-08-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR090047A1 (es) 2011-12-30 2014-10-15 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
EP3466973A1 (en) 2012-11-01 2019-04-10 AbbVie Inc. Stable dual variable domain immunoglobulin protein formulations
TWI601745B (zh) 2012-11-01 2017-10-11 艾伯維有限公司 抗－ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
SG11201507423YA (en) 2013-03-15 2015-10-29 Abbvie Inc DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
JP2016185961A (ja) 2016-10-27
SG183872A1 (en) 2012-11-29
PE20130580A1 (es) 2013-06-02
ZA201206552B (en) 2013-05-29
US9469689B2 (en) 2016-10-18
AU2011223919A1 (en) 2012-10-25
CL2012002416A1 (es) 2013-09-06
CA2791631A1 (en) 2011-09-09
DOP2012000240A (es) 2013-02-15
UA112743C2 (uk) 2016-10-25
AU2011223919B2 (en) 2015-03-19
EP3072904A1 (en) 2016-09-28
CR20120454A (es) 2013-03-19
KR101853278B1 (ko) 2018-05-02
MX2012010128A (es) 2013-04-11
SG10201501562VA (en) 2015-04-29
JP2013520993A (ja) 2013-06-10
EP2542582A2 (en) 2013-01-09
EP3680253A3 (en) 2020-09-30
US20210009681A1 (en) 2021-01-14
EP3680253A2 (en) 2020-07-15
US20110217237A1 (en) 2011-09-08
EP2542582A4 (en) 2013-12-04
UY33254A (es) 2011-09-30
UY39024A (es) 2021-02-26
AR080452A1 (es) 2012-04-11
RU2605928C2 (ru) 2016-12-27
US20190315855A1 (en) 2019-10-17
NZ602734A (en) 2014-10-31
ECSP12012194A (es) 2013-01-31
TW201134487A (en) 2011-10-16
MX348312B (es) 2017-06-06
CN105037543A (zh) 2015-11-11
RU2016146198A3 (es) 2020-05-18
WO2011109298A2 (en) 2011-09-09
MY160628A (en) 2017-03-15
US20160031986A1 (en) 2016-02-04
TWI511742B (zh) 2015-12-11
RU2016146198A (ru) 2018-12-19
CN102906113A (zh) 2013-01-30
KR20120135419A (ko) 2012-12-13
WO2011109298A3 (en) 2011-11-24
JP5964249B2 (ja) 2016-08-03
DOP2021000013A (es) 2021-03-15
RU2012141881A (ru) 2014-04-10
US9115195B2 (en) 2015-08-25
KR20180044441A (ko) 2018-05-02
CN105037543B (zh) 2020-11-03
GT201200253A (es) 2013-09-11
CN102906113B (zh) 2015-08-12
BR112012021941A2 (pt) 2022-02-01

Similar Documents

Publication Publication Date Title
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
DOP2013000219A (es) Anticuerpos imitadores de receptores de celulas t especificos para peptido wt1 unido a hla-a2
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
PH12018500131A1 (en) Il22 immunoconjugates
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
NZ764875A (en) Human monoclonal antibodies to ganglioside gd2
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2022001731A (es) Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12.
ECSP12011702A (es) Proteínas terapéuticas de unión a dll4